What was the primary endpoint measured in the ULTIMATE trial?

• A. TVF at 6 months
• B. Cardiac death rate
• C. TVF at 12 months
• D. Angiographic restenosis

Answer: (C)

The primary endpoint measured in the ULTIMATE trial was TVF (Target Vessel Failure) at 12 months. Target Vessel Failure is a composite measure that includes events such as cardiac death, myocardial infarction, and target vessel revascularization, making it a comprehensive indicator of treatment effectiveness in the context of coronary interventions.

Measuring TVF at 12 months allows researchers to assess the long-term efficacy of a treatment strategy in preventing major adverse cardiac events related to a specific vessel, which is crucial for understanding the durability of the intervention's results. This endpoint is particularly relevant in trials focused on cardiac interventions as it encompasses both immediate and sustained outcomes over a significant follow-up period.

While other options like TVF at 6 months, cardiac death rate, and angiographic restenosis are important metrics in cardiovascular research, they do not capture the full scope of long-term patient outcomes as effectively as the TVF at 12 months. The chosen endpoint aligns with the trial's aim to provide robust evidence supporting treatment options for patients with coronary artery disease.